Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 17;38(49):7702-7707.
doi: 10.1016/j.vaccine.2020.09.042. Epub 2020 Oct 16.

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Marc Gurwith  1 , Richard C Condit  2 , Jean-Louis Excler  3 , James S Robertson  4 , Denny Kim  5 , Patricia E Fast  6 , Stephen Drew  7 , David Wood  4 , Bettina Klug  8 , Mike Whelan  9 , Tamala Mallett Moore  10 , Najwa Khuri-Bulos  11 , Emily R Smith  12 , Robert T Chen  1 , Sonali Kochhar  13 ; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG
Affiliations
Review

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Marc Gurwith et al. Vaccine. .

Abstract

Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.

Keywords: Attenuated; Benefit-risk; Brighton Collaboration; CEPI; COVID-19; Live; Safety; Template; Vaccine; Viral.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI) Vaccine. 2002;21(3–4):298–302. - PubMed
    1. Chen R.T., Carbery B., Mac L., Berns K.I., Chapman L., Condit R.C., et al. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) Vaccine. 2015;33(1):73–75. doi: 10.1016/j.vaccine.2014.09.035. - DOI - PMC - PubMed
    1. Monath T.P., Seligman S.J., Robertson J.S., Guy B., Hayes E.B., Condit R.C., et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015;33(1):62–72. doi: 10.1016/j.vaccine.2014.10.004. - DOI - PMC - PubMed
    1. Clarke D.K., Hendry R.M., Singh V., Rose J.K., Seligman S.J., Klug B., et al. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine. 2016;34(51):6597–6609. doi: 10.1016/j.vaccine.2016.06.071. - DOI - PMC - PubMed
    1. Monath T.P., Fast P.E., Modjarrad K., Clarke D.K., Martin B.K., Fusco J., et al. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. Vaccine X. 2019;1 doi: 10.1016/j.jvacx.2019.100009. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources